ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL

Ignacio Marín-Jiménez  ¹     Stefan Schreiber  ²     Scott Lee  ³     C. Janneke van der Woude  ⁴     Doug Wolf  ⁵     Elisabeth Schnoy  ⁶     Bruce Salzberg  ⁷     Christopher Busse  ⁸     Maciek Nazar  ⁹     Wayne Langholff  ¹⁰     Chris Gasink  ¹⁰     Thomas Baker  ¹⁰     Bridget Godwin  ¹⁰     Brian G. Feagan  ^11    
1 Hospital Universitario Gregorio Marañón, IiSGM, Madrid, Spain
² Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
³ University of Washington, Seattle, United States
⁴ Erasmus University Medical Center, Rotterdam, Netherlands
⁵ Atlanta Gastroenterology Associates, Atlanta, United States
⁶ University Hospital of Augsburg, Augsburg, Germany
⁷ IBD Center of Atlanta, Atlanta, United States
⁸ Janssen Scientific Affairs, LLC, Horsham, United States
⁹ Janssen-Cilag Polska Sp. z o.o., Warsaw, Poland
¹⁰ Janssen Research & Development, LLC, Spring House, United States
¹¹ University of Western Ontario, London, Canada

Topic
IBD

Session
Sequential therapies in IBD: Raising the bar

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)